Market Place
Sourcing Support
Sumitomo Pharma Oncology to Present Preliminary Data Evaluating TP-3654
03 Nov 2022 //
PRNEWSWIRE
Sumitomo Pharma Oncology Receives ODD for DSP-0390 for Brain Cancer
18 Jul 2022 //
PRNEWSWIRE
Sumitomo Presents New Data from Novel Cancer Therapeutics at AACR
08 Apr 2022 //
PRNEWSWIRE
Sumitomo Dainippon Provides Update on Phase 3 Study of DSP-7888 in Glioblastoma
14 Dec 2021 //
PRNEWSWIRE
Sumitomo Begins Dosing in Phase 1 Dose Expansion Study of TP-1287
03 Nov 2021 //
PRNEWSWIRE
Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study
09 Feb 2021 //
PRNEWSWIRE
Sumitomo Dainippon Announces First Patient Dosed in Ph 1/2 Study of TP-0184
19 Jan 2021 //
PRNEWSWIRE
Sumitomo Oncology Announces First Patient Dosed in Ph 1/2 Study of TP-0184
18 Jan 2021 //
PRNEWSWIRE
Lynn Seely hits the exit as Myovant graduates to commercial space- Amgen vet
05 Jan 2021 //
ENDPTS
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201
05 Dec 2020 //
PRNEWSWIRE
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2
26 Oct 2020 //
PRNEWSWIRE
Dosing underway in Sumitomo Dainippon`s TP-1454 early-stage cancer study
09 Oct 2020 //
PRESSRELEASE
SumitomoDainipponPharma Oncology Presents PhI Study Evaluating Dubermatinib:ESMO
18 Sep 2020 //
BIOSPACE
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger
30 Jun 2020 //
PRNEWSWIRE
Tolero Presents Biomarker Identification Strategies for Invg Agents Alvocidib
22 Jun 2020 //
PRNEWSWIRE
Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study
12 Jun 2020 //
PRNEWSWIRE
Tolero Presents Findings from First Clinical Studies TP-1287 and TP-3654
29 May 2020 //
PRNEWSWIRE
Tolero Pharmaceuticals sINDA for Experimental PKM2 Activator TP-1454
19 May 2020 //
PR NEWSWIRE
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study
14 May 2020 //
PRNEWSWIRE
Boston Biomedical Announces First Patient Dosed in Ph 1 Study TP-3654
07 Apr 2020 //
PR NEWSWIRE
Boston Biomedical, Announces 1 Study of Investigational Agent TP-3654
06 Apr 2020 //
PR NEWSWIRE
Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study
15 Jan 2020 //
PR NEWSWIRE
Boston Biomedical Launches Cancer Research Alliance with Three Oncology Centers
03 Dec 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.